← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

Genfit S.A. (GNFT) 10-Year Financial Performance & Capital Metrics

GNFT • • Industrial / General
HealthcareBiotechnologyMetabolic & Liver DiseasesNASH & Liver Diseases
AboutGenfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.Show more
  • Revenue $67M +134.6%
  • EBITDA $5M +120.1%
  • Net Income $2M +105.2%
  • EPS (Diluted) 0.03 +105.2%
  • Gross Margin 99.55% +0.8%
  • EBITDA Margin 7.47% +108.6%
  • Operating Margin 4.9% +105.3%
  • Net Margin 2.25% +102.2%
  • ROE 2.2% +106.2%
  • ROIC 4.48% +110.6%
  • Debt/Equity 0.90 -13.1%
  • Interest Coverage 0.69 +112.0%
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓FCF machine: 21.2% free cash flow margin
  • ✓Momentum leader: RS Rating 88 (top 12%)
  • ✓High quality earnings: Operating CF exceeds net income
  • ✓Strong 5Y sales CAGR of 16.8%

✗Weaknesses

No significant weaknesses identified

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y45.15%
5Y16.79%
3Y-5.77%
TTM9.75%

Profit (Net Income) CAGR

10Y-
5Y-
3Y-71.81%
TTM-161.19%

EPS CAGR

10Y-
5Y-
3Y-71%
TTM-212.82%

ROCE

10Y Avg-19.12%
5Y Avg-9.9%
3Y Avg-9.26%
Latest3.1%

Peer Comparison

NASH & Liver Diseases
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
MAZEMaze Therapeutics, Inc.1.92B39.81511.7031.18%-33.24%3.91%0.14
GNFTGenfit S.A.313.52M6.27209134.56%-14.12%-31.42%4.54%0.90
GYREGyre Therapeutics, Inc.741.77M7.70154-6.78%6.2%4.84%0.02
TVRDTvardi Therapeutics, Inc.42.31M4.51-0.10-65.96%-317.54%-63.46%
UNCYUnicycive Therapeutics, Inc.134.75M6.27-1.12-100%-89.15%0.10
GLTOGalecto, Inc.38.32M23.95-1.29-237.68%0.00
IVAInventiva S.A.1.17B6.12-1.73-47.37%-13.75%
AKBAAkebia Therapeutics, Inc.355.59M1.34-4.06-17.7%-7.07%-38.24%

Profit & Loss

Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Sales/Revenue+527K284K118K69K30.84M765K80.07M20.2M28.57M67M
Revenue Growth %-0.67%-0.46%-0.58%-0.42%445.94%-0.98%103.67%-0.75%0.41%1.35%
Cost of Goods Sold+1.93M1.99M2.23M1.85M177K202K161K248K341K300K
COGS % of Revenue3.66%6.99%18.89%26.87%0.01%0.26%0%0.01%0.01%0%
Gross Profit+-1.4M-1.7M-2.11M-1.78M30.66M563K79.91M19.95M28.22M66.7M
Gross Margin %-2.66%-5.99%-17.89%-25.87%0.99%0.74%1%0.99%0.99%1%
Gross Profit Growth %-7.68%-0.21%-0.24%0.15%18.18%-0.98%140.93%-0.75%0.41%1.36%
Operating Expenses+16.27M32.46M54.58M67.7M88.67M78.35M53.54M47.5M54.8M63.42M
OpEx % of Revenue30.87%114.28%462.57%981.16%2.88%102.42%0.67%2.35%1.92%0.95%
Selling, General & Admin9.13M11.65M13.41M4.5M30.97M25.49M17.69M17.4M8.04M20.13M
SG&A % of Revenue17.32%41.04%113.61%65.14%1%33.32%0.22%0.86%0.28%0.3%
Research & Development5.39M19.19M35.09M47.66M66.17M59.1M35.17M35.82M46.71M47.21M
R&D % of Revenue10.23%67.56%297.42%690.74%2.15%77.25%0.44%1.77%1.64%0.7%
Other Operating Expenses1.75M1.61M6.08M6.41M-8.47M-6.23M682K-5.72M53K-3.92M
Operating Income+-17.68M-34.16M-56.7M-69.48M-57.83M-82.9M31.82M-27.29M-26.58M3.28M
Operating Margin %-33.54%-120.27%-480.47%-1007.01%-1.88%-108.36%0.4%-1.35%-0.93%0.05%
Operating Income Growth %-0.02%-0.93%-0.66%-0.23%0.17%-0.43%1.38%-1.86%0.03%1.12%
EBITDA+-17.35M-33.36M-55.16M-68.05M-52.58M-79.34M34.56M-25.46M-24.93M5M
EBITDA Margin %-32.92%-117.46%-467.48%-986.22%-1.71%-103.71%0.43%-1.26%-0.87%0.07%
EBITDA Growth %-0.02%-0.92%-0.65%-0.23%0.23%-0.51%1.44%-1.74%0.02%1.2%
D&A (Non-Cash Add-back)327K799K1.53M1.44M5.25M3.56M2.74M1.83M1.65M1.72M
EBIT-17.68M-34.16M-56.69M-69.53M-54.28M-76.58M32.16M-27.64M-23.89M6.62M
Net Interest Income+437K193K-1.94M-10.79M-8.83M-10.35M-4.68M-4.27M-2.94M-3M
Interest Income437K316K389K202K2.63M1.44M274K137K1.71M1.79M
Interest Expense0123K2.33M10.99M11.45M11.79M4.96M4.41M4.65M4.78M
Other Income/Expense541K526K-2.45M-10.39M-7.89M-18.75M37.66M3.45M-1.93M-1.43M
Pretax Income+-17.14M-33.63M-58.22M-79.88M-65.72M-101.65M69.47M-23.84M-28.51M1.85M
Pretax Margin %-32.51%-118.42%-493.38%-1157.61%-2.13%-132.87%0.87%-1.18%-1%0.03%
Income Tax+227K35K384K-354K-576K-428K2.21M-116K380K340K
Effective Tax Rate %1%1%1.01%1%0.99%1%0.97%1%1.01%0.82%
Net Income+-17.14M-33.67M-58.6M-79.52M-65.14M-101.22M67.26M-23.72M-28.89M1.51M
Net Margin %-32.51%-118.55%-496.64%-1152.48%-2.11%-132.32%0.84%-1.17%-1.01%0.02%
Net Income Growth %-0.01%-0.96%-0.74%-0.36%0.18%-0.55%1.66%-1.35%-0.22%1.05%
Net Income (Continuing)-17.13M-33.66M-55.73M-79.52M-65.14M-101.22M67.26M-23.72M-28.89M1.51M
Discontinued Operations0000000000
Minority Interest0000000000
EPS (Diluted)+-0.69-1.25-1.88-2.55-1.76-2.601.23-0.48-0.580.03
EPS Growth %0.07%-0.81%-0.5%-0.36%0.31%-0.48%1.47%-1.39%-0.21%1.05%
EPS (Basic)-0.69-1.28-1.88-2.55-1.76-2.601.50-0.48-0.580.03
Diluted Shares Outstanding24.7M26.85M31.17M31.17M36.99M38.86M55.61M49.67M49.7M50.23M
Basic Shares Outstanding24.7M26.35M31.16M31.17M36.99M38.86M44.74M49.67M49.82M50.23M
Dividend Payout Ratio----------

Balance Sheet

Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Total Current Assets+66.75M162M283.57M218.12M290.75M184.72M268.1M158.46M113.11M92.77M
Cash & Short-Term Investments60.11M152.28M273.82M207.24M276.75M171.03M258.76M140.55M77.79M81.79M
Cash Only60.11M152.28M273.82M207.24M276.75M171.03M258.76M136M77.79M81.79M
Short-Term Investments00000004.55M00
Accounts Receivable6.01M8.39M417K395K12.03M11.92M7.24M15.91M32.71M7.56M
Days Sales Outstanding4.16K10.79K1.29K2.09K142.435.69K32.99287.48417.9341.21
Inventory28K14K4K4K4K4K4K4K4K4K
Days Inventory Outstanding5.292.570.660.798.257.239.075.894.284.87
Other Current Assets-9K726K7.88M8.77M-1K00001K
Total Non-Current Assets+2.5M4.22M9.61M11.36M19.1M13.9M13.62M57.08M60.76M58.66M
Property, Plant & Equipment1.32M3.01M6.32M7.76M16.45M11.65M9.02M8.21M7.87M7.59M
Fixed Asset Turnover0.40x0.09x0.02x0.01x1.87x0.07x8.88x2.46x3.63x8.82x
Goodwill0000000000
Intangible Assets562K667K636K795K920K791K174K43.96M48.76M48M
Long-Term Investments113K109K267K770K1.73M1.46M4.43M4.91M2.82M1.88M
Other Non-Current Assets7K433K1K2.03M-1K-11.95M3K-55.78M1.3M1.18M
Total Assets+69.26M166.21M293.18M229.48M309.85M198.61M281.72M215.54M173.87M151.42M
Asset Turnover0.01x0.00x0.00x0.00x0.10x0.00x0.28x0.09x0.16x0.44x
Asset Growth %-0.2%1.4%0.76%-0.22%0.35%-0.36%0.42%-0.23%-0.19%-0.13%
Total Current Liabilities+8.61M17.56M27.11M39.25M43.49M31.07M62.84M39.37M38.48M75.16M
Accounts Payable5.28M13.34M19.05M32.65M32.75M20.34M12.3M8.61M10.45M18.39M
Days Payables Outstanding997.092.45K3.12K6.43K67.54K36.75K27.89K12.68K11.18K22.37K
Short-Term Debt1.22M1.17M2.74M2.64M2.42M2.26M1.1M4.05M6.85M55.44M
Deferred Revenue (Current)29K1K1K1K139K124K1000K1000K1000K0
Other Current Liabilities2.09M2.97M378K112K5.56M1.03M313K61K40K39K
Current Ratio7.75x9.22x10.46x5.56x6.68x5.95x4.27x4.02x2.94x1.23x
Quick Ratio7.75x9.22x10.46x5.56x6.68x5.95x4.27x4.02x2.94x1.23x
Cash Conversion Cycle3.17K8.34K-1.83K-4.34K-67.39K-31.05K-27.85K-12.38K-10.76K-22.32K
Total Non-Current Liabilities+5.23M5.86M161.85M169.29M182.29M183.71M99.79M81.64M67.44M7.04M
Long-Term Debt4.48M4.7M160.05M165.05M168.91M173.3M66.07M64.67M57.45M1.64M
Capital Lease Obligations0307K1.47M1.38M10.17M8.05M5.98M5.53M4.81M3.92M
Deferred Tax Liabilities743K0321K1.77M1.19M767K602K510K455K145K
Other Non-Current Liabilities742K849K937K1.08M2.02M1.6M1.32M1.23M978K1.34M
Total Liabilities13.84M23.42M188.95M208.54M225.79M214.78M162.62M121.01M105.92M82.2M
Total Debt+5.71M6.25M163.75M169.59M183.62M185.69M74.23M75.28M70.18M62.13M
Net Debt-54.41M-146.03M-110.07M-37.66M-93.13M14.66M-184.52M-60.73M-7.61M-19.66M
Debt / Equity0.10x0.04x1.57x8.10x2.18x-0.62x0.80x1.03x0.90x
Debt / EBITDA------2.15x--12.41x
Net Debt / EBITDA-------5.34x---3.93x
Interest Coverage--277.71x-24.31x-6.32x-5.05x-7.03x6.42x-6.19x-5.72x0.69x
Total Equity+55.42M142.8M104.23M20.94M84.06M-16.16M119.1M94.53M67.95M69.22M
Equity Growth %-0.21%1.58%-0.27%-0.8%3.01%-1.19%8.37%-0.21%-0.28%0.02%
Book Value per Share2.245.323.340.672.27-0.422.141.901.371.38
Total Shareholders' Equity55.42M142.8M104.23M20.94M84.06M-16.16M119.1M94.53M67.95M69.22M
Common Stock5.99M7.79M7.79M7.8M9.71M9.72M12.45M12.46M12.46M12.5M
Retained Earnings-68.63M-102.32M-161.13M-238.42M-303.48M-404.85M-337.82M-361.27M-389.79M-390.57M
Treasury Stock00-127K00000-970K0
Accumulated OCI15K21K-8K6K14K-92K22K-1.34M996K347K
Minority Interest0000000000

Cash Flow

Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Cash from Operations+-14.87M-27.23M-49.86M-56.08M-47.68M-96.37M99.92M-72.64M-55.43M15.55M
Operating CF Margin %-28.22%-95.87%-422.51%-812.77%-1.55%-125.98%1.25%-3.6%-1.94%0.23%
Operating CF Growth %0.04%-0.83%-0.83%-0.12%0.15%-1.02%2.04%-1.73%0.24%1.28%
Net Income-17.14M-33.67M-58.6M-79.52M-65.14M-101.22M67.26M-23.72M-28.89M1.51M
Depreciation & Amortization327K816K1.41M1.82M5.41M3.56M2.74M1.83M1.65M1.72M
Stock-Based Compensation2.01M11K278K787K1.66M1.24M470K245K578K0
Deferred Taxes3K35K384K-354K-576K-428K2.21M-116K380K0
Other Non-Cash Items-17K-321K1.39M10.5M11.33M11.61M-32.45M3.91M-1.33M3.88M
Working Capital Changes-60K5.9M5.28M10.33M-356K-11.13M59.68M-54.79M-27.82M8.43M
Change in Receivables946K-2.94M-2.11M-724K-1.64M318K4.34M-8.56M-17.42M23.96M
Change in Inventory219K14K10K0000017.42M0
Change in Payables-1.46M8.83M7.38M11.06M1.28M-11.45M55.34M-46.23M-10.4M-15.53M
Cash from Investing+3.5M-2.09M-2.95M-3.99M327K-966K-3.38M-46.27M2.23M-1.04M
Capital Expenditures-790K-2.04M-2.8M-2.94M-2.03M-900K-537K0-2.49M-979K
CapEx % of Revenue1.5%7.17%23.73%42.58%0.07%1.18%0.01%-0.09%0.01%
Acquisitions----------
Investments----------
Other Investing4.29M1K-148K2K2.52M0308K271K172K80K
Cash from Financing+-520K121.48M174.35M-6.51M116.86M-8.26M-8.92M-3.79M-5.1M-10.57M
Debt Issued (Net)----------
Equity Issued (Net)----------
Dividends Paid0000000000
Share Repurchases----------
Other Financing280K7K-1.33M-6.31M-7.74M-6.32M-1.83M-2.04M-493K-1.46M
Net Change in Cash----------
Free Cash Flow+-15.66M-29.26M-52.66M-59.02M-49.71M-97.27M99.38M-72.64M-57.92M14.22M
FCF Margin %-29.72%-103.04%-446.24%-855.35%-1.61%-127.15%1.24%-3.6%-2.03%0.21%
FCF Growth %0.03%-0.87%-0.8%-0.12%0.16%-0.96%2.02%-1.73%0.2%1.25%
FCF per Share-0.63-1.09-1.69-1.89-1.34-2.501.79-1.46-1.170.28
FCF Conversion (FCF/Net Income)0.87x0.81x0.85x0.71x0.73x0.95x1.49x3.06x1.92x10.32x
Interest Paid0000000000
Taxes Paid0000000000

Key Ratios

Metric2015201620172018201920202021202220232024
Return on Equity (ROE)-27.23%-33.97%-47.45%-127.06%-124.08%-298.13%130.68%-22.21%-35.57%2.2%
Return on Invested Capital (ROIC)-1305.85%-------60.55%-42.35%4.48%
Gross Margin-266.41%-598.94%-1788.98%-2586.96%99.43%73.59%99.8%98.77%98.81%99.55%
Net Margin-3251.42%-11854.58%-49664.41%-115247.83%-211.24%-13231.5%84%-117.45%-101.15%2.25%
Debt / Equity0.10x0.04x1.57x8.10x2.18x-0.62x0.80x1.03x0.90x
Interest Coverage--277.71x-24.31x-6.32x-5.05x-7.03x6.42x-6.19x-5.72x0.69x
FCF Conversion0.87x0.81x0.85x0.71x0.73x0.95x1.49x3.06x1.92x10.32x
Revenue Growth-67.36%-46.11%-58.45%-41.53%44594.2%-97.52%10366.54%-74.78%41.45%134.56%

Frequently Asked Questions

Valuation & Price

Genfit S.A. (GNFT) has a price-to-earnings (P/E) ratio of 209.0x. This suggests investors expect higher future growth.

Growth & Financials

Genfit S.A. (GNFT) reported $116.8M in revenue for fiscal year 2024. This represents a 4847% increase from $2.4M in 2011.

Genfit S.A. (GNFT) grew revenue by 134.6% over the past year. This is strong growth.

Genfit S.A. (GNFT) reported a net loss of $16.5M for fiscal year 2024.

Dividend & Returns

Genfit S.A. (GNFT) has a return on equity (ROE) of 2.2%. This is below average, suggesting room for improvement.

Genfit S.A. (GNFT) had negative free cash flow of $47.2M in fiscal year 2024, likely due to heavy capital investments.

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.